This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways
Leukemia Open Access 12 April 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Accession codes
References
Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, Oka Y et al. Wilm's tumour gene 1 (WT1) in human neoplasia. Leukemia 2005; 19: 1318–1323.
Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA . The Wilm's tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001; 20: 1897–1909.
King-Underwood L, Pritchard-Jones K . Wilm's tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998; 91: 2961–2968.
Nyvold CG, Stentoft J, Braendstrup K, Melsvik D, Moestrup SK, Juhl-Christensen C et al. Wilm's tumor 1 mutation accumulated during therapy in acute myeloid leukemia: biological and clinical implications. Leukemia 2006; 20: 2051–2054.
Fitzgibbon J, Smith LL, Raghavan M, Smith ML, Debernardi S, Skoulakis S et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005; 65: 9152–9154.
Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD . Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2006, [E-pub ahead of print].
Noguera NI, Ammatuna E, Zangrilli D, Lavorgna S, Divona M, Buccisano F et al. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 2005; 19: 1479–1482.
Lin LI, Lin TC, Chou WC, Tang JL, Lin DT, Tien HF . A novel fluorescence-based multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias. Leukemia 2006; 20: 1899–1903.
Acknowledgements
This work was supported by the Newman Foundation, Cancer Research UK and the Royal London Charitable Foundation. We would also like to thank Iram Gull and Victoria Miller for sample collection and storage, Susan Weiss for assistance in preparing the figures and Rifca le Dieu, Kajsa Paulson and David Taussig for helpful discussion on the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Summers, K., Stevens, J., Kakkas, I. et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 21, 550–551 (2007). https://doi.org/10.1038/sj.leu.2404514
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404514
This article is cited by
-
Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant
Bone Marrow Transplantation (2022)
-
Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways
Leukemia (2017)
-
A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia
The Pharmacogenomics Journal (2016)
-
Significance of oncogenes and tumor suppressor genes in AML prognosis
Tumor Biology (2016)
-
WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups
Leukemia (2015)